Warm Autoimmune Hemolytic Anemia (wAIHA)
| Overview / Abstract: |
Warm autoimmune hemolytic anemia (wAIHA) is the most common type (60-70%) of autoimmune hemolytic anemia (AIHA). In most cases, wAIHA is due an immunoglobulin G (IgG) autoantibody that binds to red blood cells (RBC), leading to hemolysis. Current recommendations for managing people with wAIHA are largely based on case series and retrospective studies involving off-label medications. Also, while there are currently no medications specifically approved to treat wAIHA, data are emerging on new therapies under investigation which may impact treatment in the future. This 60-minute CME program, hosted by Irina Murakhovskaya, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in New York, NY and Bruno Fattizzo, MD, of the University of Milan and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, in Milan, Italy, describes current best practices for diagnosing and managing patients with wAIHA. |
|
Expiration |
May 31, 2024 |
|
Discipline(s) |
Physician CME, Physician Assistant CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
1.0 hour |
|
Accreditation |
American Academy of CME |
|
Presenters / Authors / Faculty |
Irina Murakhovskaya, MD Bruno Fattizzo, MD |
|
Sponsors / Supporters / Grant Providers |
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC |
|
Keywords / Search Terms |
CheckRare rare disease, rare blood disorder, Warm autoimmune hemolytic anemia, wAIHA, autoimmune hemolytic anemia, AIHA, immunoglobulin G, IgG autoantibody, red blood cells, hemolysis Free CE CME |
|